checkAd

     332  0 Kommentare SORRENTO DEVELOPS STI-4398 (COVIDTRAP PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)

    • COVIDTRAPTM is a proprietary ACE2-Fc protein that binds to the S1 domain of the spike protein of the SARS-CoV-2 virus;
    • COVIDTRAP is designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial cells, which is expected to effectively interrupt the viral life cycle;
    • COVIDTRAP is engineered with a long half-life to provide prophylactic measures for at-risk populations (healthcare workers) with frequent exposure to the SARS-CoV-2 virus;
    • COVIDTRAP preserves the ACE2 enzymatic activity, which is important in maintaining normal blood pressure and healthy blood flow into the infected lung tissues when used in advanced COVID-19 patients; and
    • STI-4398 is in the cGMP cell line development stage and could be ready for large-scale production in Sorrento’s cGMP facilities in San Diego for human clinical trials and commercialization upon receipt of requisite regulatory approvals.   

    SAN DIEGO, March 20, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has produced a preclinical batch of the STI-4398 (COVIDTRAP) protein to immediately commence testing its neutralization and blocking activity in preventing SARS-CoV-2 virus from infecting ACE2-expressing cells.

    STI-4398 is a proprietary ACE2 (angiotensin-converting enzyme 2)-Fc fusion protein (COVIDTRAP). The STI-4398 protein binds to the S1 domain of the spike protein, which is expected to block the spike protein of the SARS-CoV-2 virus to bind the ACE2 receptors present on the target respiratory epithelial cells. Without the ability to penetrate target cells, the SARS-CoV-2 virus cannot replicate and spread itself. By interfering with the viral infection cycle, STI-4398 might be the most effective way to prevent an infection to progress to a fully advanced COVID-19 disease. This approach could be ideal in generating passive immunity and shielding at-risk populations, including healthcare providers, the elderly population or patients with compromised immune systems, from developing the COVID-19 disease after viral exposure.

    The STI-4398 COVIDTRAP preserves the ACE2 enzyme activity in converting angiotensin II to angiotensin 1-7, resulting in reduced vasoconstriction and increased blood flow to the infected lung tissue. It could potentially confer organ protection and lessen severe acute respiratory distress syndrome in COVID-19 patients. Although STI-4398’s primary functionality is to interfere with the viral infection cycle, the COVIDTRAP protein with active ACE2 enzyme may have therapeutic potential for late-stage COVID-19 disease.

    Seite 1 von 4




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    SORRENTO DEVELOPS STI-4398 (COVIDTRAP PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19) COVIDTRAPTM is a proprietary ACE2-Fc protein that binds to the S1 domain of the spike protein of the SARS-CoV-2 virus;COVIDTRAP is designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial cells, which is expected to …